Cytokines have been associated with symptoms and adverse outcomes in breast cancer. Overexpression of ERBB2 (c-erb-b2; formerly HER2/neu), which is a member of the epidermal growth receptor family, is associated with involvement of lymph nodes, large tumor size, high grade, steroid receptor negativity, aneuploidy, high proliferation rate, and low overall survival in breast cancer. The aim of the study was to examine whether ERBB2 amplification has any effect on circulating levels of tumor necrosis factor-alpha (TNF-α) and interleukin-2 (IL-2) in breast cancer patients.
Material and methods
Fifty patients with primary breast carcinoma, classified as either ERBB2 (+) or (-) by the fluorescence in situ hybridization (FISH) technique, were included in the study. Cytokines were studied by ELISA according to the procedure described in the commercial kit.
Results
IL-2 levels were found significantly higher in ERBB2+ patients than in controls (p<0.05). A significant negative correlation existed between ERBB2 positivity and estrogen receptor status (p=0.004). Plasma TNF-α and IL-2 levels were positively correlated in ERBB2+ breast cancer patients (p<0.01).
Conclusion
The increase in IL-2 concentrations observed in our study suggests an activation of T cells by ERBB2 peptides.
CroweJ.P., PatrickR.J., RybickiL.A.A data model to predict HER2 status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institution. Breast2006; 15: 728–35.
2.
RossJ.S., FletcherJ.A.The Her-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist1998; 3: 237–52.
3.
WitzelI., ThomssenC., KrenkelS.Clinical utility of determination of HER-2/neu and EGFR fragments in serum of patients with metastatic breast cancer. Int J Biol Markers2006; 21: 131–40.
4.
SaghatchianM., GuepratteS., HaceneK., NeumannR., FloirasJ.L., PichonM.F.Serum HER-2 extracellular domain: relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients. Int J Biol Markers2004; 19: 14–22.
5.
LuftnerD., HenschkeP., KafkaA.Discordant results obtained for different methods of HER-2/neu testing in breast cancer: a question of standardization, automation and timing. Int J Biol Markers2004; 19: 1–13.
6.
MüllerV., ThomssenC., KarakasC.Quantitative assessment of HER-2/neu protein concentration in breast cancer by enzyme-linked immunosorbent assay. Int J Biol Markers2003; 18: 13–20.
7.
TangP., HungM.C., KlostergaardJ.TNF cytotoxicity: effects of HER-2/neu expression and inhibitors of ADP-ribosylation. Lymphokine Cytokine Res1994; 13: 117–23.
8.
ChaveyC., BibeauF., Gourgou-BourgadeS.Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res2007; 9: R15.
9.
LyonD.E., McCainN.L., WalterJ., SchubertC.Cytokine comparisons between women with breast cancer and women with a negative breast biopsy. Nurs Res2008; 57: 51–8.
10.
WeitsmanG.E., RavidA., LiebermanU.A., KorenR.Vitamin D enhances caspase-dependent and independent TNF-induced breast cancer cell death: the role of reactive oxygen species. Ann N Y Acad Sci2003; 1010: 437–40.
11.
LyuM.A., RosenblumM.G.The immunocytokine scFv23/TNF sensitizes HER-2/neu-overexpressing SKBR-3 cells to tumor necrosis factor (TNF) via up-regulation of TNF receptor-1. Mol Cancer Ther2005; 8: 1205–13.
12.
ZielinskiC.C., BudinskyA.C., WagnerT.M.Defect of tumor necrosis factor-alpha (TNF-alpha) production and TNF-alpha-induced ICAM-1 -expression in BRCA1 mutations carriers. Breast Cancer Res Treat2003; 81: 99–1 05.
13.
Sheen-ChenS.M., ChenW.J., EngH.L., ChouF.F.Serum concentration of tumor necrosis factor in patients with breast cancer. Breast Cancer Res Treat1997; 43: 211–5.
14.
MelczerZ., BanhidyF., CsomorS., SiklosP., DworakO., CsehK.ErbB-2/HER-2 protein expression, serum tumour necrosis factor-alpha (TNF-alpha) and soluble tumour necrosis factor receptor-2 (TNFR-2) concentrations in human carcinoma of the uterine cervix. Eur J Gynaecol Oncol2003, 24: 138–142.
15.
Garcia-TunonI., RicoteM., RuizA., FraileB., PaniaguaR., RoyuelaM.Interleukin-2 and its receptor complex (α, β and γ chains) in in situ and infiltrative human breast cancer: an immunohistochemical comparative study. Breast Cancer Res2004; 6: R1–7.
16.
AzzaroneB., Pottin-ClemenceauC., KriefP.Are interleukin-2 and interleukin-15 tumor promoting factors for human nonhematopoietic cells?Eur Cytokine Netw1996; 7: 27–36.
17.
SaksS., RosenblumM.Recombinant human TNF-α: preclinical studies and results from early clinical trial. Immunol Ser1992, 56, 567–87.
18.
NakamotoT., InagawaH., TakagiK., SomaG.A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors. Anticancer Res2000; 20: 4087–96.
19.
HoffmannM., SchmidtM., WelsW.Activation of EGF receptor family members suppresses the cytotoxic effects of tumor necrosis factor-α. Cancer Immunol Immunother1998; 47: 167–75.
20.
SleijferS., AsschertJ.G.W., Timmer-BosschaH., MulderN.H.Enhanced sensitivity to tumor necrosis factor-α in doxorubicin-resistant tumor cell lines due to downregulated c-erbB2. Int J Cancer1998; 77: 101–6.
21.
LichtensteinA., BerensonJ., GeraJ.F., WaldburgerK., Martinez-MazaO., BerekJ.S.Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/neu oncogenes. Cancer Res1990; 50: 7364–70.
22.
LichtensteinA., FadyC., GeraJ.F.Effects of beta-2 microglobulin anti-sense oligonucleotides on sensitivity of HER2/neu oncogene-expressing and nonexpressing target cells to lymphocyte-mediated lysis. Cell Immunol1992; 141: 219–32.
23.
ZhouB.P., HuM.C., MillerS.A.HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem2000; 275: 8027–31.
24.
WangX., LiN., LiH.Silencing of human phosphatidylethanolamine-binding protein 4 sensitizes breast cancer cells to tumor necrosis factor-α-induced apoptosis and cell growth arrest. Clin Cancer Res2005; 11: 7545–53.
25.
SzlosarekP.W., BalkwillF.R.Tumor necrosis factor alpha: a potential target for the therapy of solid tumors. Lancet Oncol2003; 4: 565–73.
26.
TartagliaL.A., WeberR.F., FigariI.S., ReynoldsC., PalladinoM.A., GoeddelD.V.The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci U S A1991; 88: 9292–6.
27.
Garcia-TunonI., RicoteM., RuizA., FraileB., PaniaguaR., RoyuelaM.Role of tumor necrosis factor-α and its receptors in human benign breast lesions and tumors (in situ and infiltrative). Cancer Sci2006; 97: 1044–9.
28.
NunesR.A., LiX., KangS.P.Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy. Int J Biol Markers2009; 24: 1–10.
29.
PusztaiL., MendozaT.R., ReubenJ.M.Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine2004; 25: 94–102.
30.
TuttleT.M., AndersonB.W., ThompsonW.E.Proliferative and cytokine response to class II HER-2/neu- associated peptides in breast cancer patients. Clin Cancer Res1998; 4: 2015–24.
31.
LaouarY., CrispeI.N.Functional flexibility in T cells: independent regulation of CD4+ T cell proliferation and effector function in vivo. Immunity2000; 13: 291–301.
32.
LeaN.C., OrrS.J., StoeberK.Commitment point during G0–G1 that controls entry into the cell cycle. Mol Cell Biol2003; 23: 2351–61.
